-
SM-102 and the Next Frontier in Targeted mRNA Delivery
2026-09-27
SM-102 offers a practical starting point for LNP-based mRNA research, but translational performance depends on more than lipid choice. Learn how to connect formulation design with targeted delivery, rigorous validation, and evidence-led development decisions.
-
Candida EV Signaling and Proteinase K in Translation
2026-09-26
A mechanistic study links Candida albicans extracellular vesicles to NRG1-dependent suppression of hyphal growth. This article examines what the findings mean for translational study design—and where Proteinase K can support adjacent DNA-preparation workflows without overstating its role in the original research.
-
Hepatocyte Arrb2 Protects Against Hepatic IRI
2026-09-26
This study links hepatocyte Arrb2 to reduced hepatic ischemia–reperfusion injury through increased 6-ketoLCA and a shift toward M2-associated macrophage polarization. Its combination of transplant-related clinical samples, a 70% mouse liver ischemia/reperfusion model, and hypoxia/reoxygenation experiments offers a framework for investigating communication between hepatocytes and macrophages.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-09-25
Breen and colleagues developed a drug-sensitized yeast platform that detects TOR-pathway growth inhibition at substantially lower concentrations than wild-type yeast and helps distinguish rapamycin-like activity from other TOR inhibition. The study also illustrates an important negative result: canagliflozin did not produce evidence of TOR inhibition in this yeast assay, underscoring the need to distinguish SGLT2-focused metabolic research from mTOR-targeted screening.
-
EDC.HCl: Practical Coupling Guide
2026-09-25
EDC.HCl is a water-soluble carbodiimide for activating carboxyl groups to support amide bond formation in peptide synthesis and bioconjugation workflows. It is intended for controlled laboratory chemistry; the available information does not establish in vivo or clinical use.
-
SD 169: Designing Better p38 MAPK Assays
2026-09-24
SD 169 (indole-5-carboxamide) offers a useful way to interrogate p38α/β signaling, but pathway inhibition and loss of p38 phosphorylation are not interchangeable outcomes. This article turns recent structural findings into practical assay-design guidance for diabetes and axonal regeneration research.
-
PEG 400 Boosts Quercetin Exposure and Anti-Inflammation
2026-09-24
A rat pharmacokinetic and inflammation study found that PEG 400 increased plasma exposure to quercetin and its glucuronide metabolite, changed their tissue distribution, and enhanced quercetin’s effect in a paw-edema model. The combined imaging and in vitro experiments point to solubility, UGT1A9 activity, and BCRP/MRP2 transport as contributing factors, while leaving the relative importance of each mechanism unresolved.
-
In Vivo CD19 CAR T Cells for Lupus
2026-09-23
The reference study presents a CD5-targeted lipid nanoparticle that delivers CD19-directed CAR mRNA directly in vivo, generating functional CAR T cells without ex vivo cell manufacturing or lymphodepletion. In MRL/lpr mice, this approach depleted pathogenic B-cell populations, reduced autoimmune inflammation, and improved renal and dermal pathology, while highlighting important translational questions about durability, safety, and delivery.
-
FLAG tag Peptide (DYKDDDDK) in Viability Workflows
2026-09-23
Learn how SKU A6002, the FLAG tag Peptide (DYKDDDDK), can support recombinant protein detection and purification workflows that accompany cell viability, proliferation, and cytotoxicity assays. This scenario-based guide emphasizes assay compatibility, storage, resin-specific elution, and practical vendor-selection criteria.
-
Nutlin-3a Workflow for MDM2-P53 Research
2026-09-22
Nutlin-3a is a practical MDM2 inhibitor for connecting p53 pathway activation with cell-cycle control, apoptosis induction, and cancer-cell phenotyping. This workflow shows how to optimize dosing, separate apoptosis from ferroptosis, and extend findings into glioblastoma assays informed by the miR-18a/ALOXE3 axis.
-
Glioblastoma Apoptotic Priming and BH3-Mimetic Therapy
2026-09-21
Koessinger and colleagues show that glioblastoma, particularly its stem-like compartment, depends on elevated anti-apoptotic BCL-xL and MCL-1 activity. Their work links this apoptotic priming to therapeutic sensitivity and supports sequential BCL-2 family protein inhibition as a preclinical strategy for overcoming treatment resistance.
-
TPCA-1: A Translational IKK-2 Inhibitor Strategy
2026-09-21
TPCA-1 offers a selective way to interrogate IKK-2-dependent NF-κB signaling while keeping inflammatory transcription distinct from RIPK1-controlled apoptosis and necroptosis. This thought-leadership guide connects mechanistic biology, assay design, rheumatoid arthritis research, and translational decision-making without overstating what preclinical evidence can establish.
-
Exosomal Egr2 Protects Neurons After Ischemic Stroke
2026-09-20
This 2025 study identifies BMSC-derived exosomal Egr2 as a regulator of neuronal injury after oxygen-glucose deprivation/reoxygenation. Its mechanistic contribution is the connection of Egr2 transcriptional control of RNF8 with RNF8-dependent ubiquitination of DAPK1, providing a molecular explanation for the protective effects of BMSC exosomes in an in vitro ischemic-stroke model.
-
Eltanexor: From Nuclear Export to CRC Assays
2026-09-19
Eltanexor (KPT-8602) offers a mechanistically focused way to study XPO1 inhibition beyond cell viability. This article translates recent Wnt/β-catenin and colorectal cancer findings into practical assay-design decisions, controls, and interpretation strategies.
-
Lactate–HMGB1 Signaling in Polymicrobial Sepsis
2026-09-19
Yang and colleagues identify lactate as an active regulator of macrophage HMGB1 modification and exosomal release, rather than only a prognostic marker of sepsis severity. Their work connects lactate uptake, p300/CBP activity, GPR81–YAP–SIRT1 signaling, endothelial permeability, and survival in polymicrobial sepsis, while defining experimental opportunities for studying inflammatory mediator release.